Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Platinum-Resistant Ovarian Cancer
NCT00097019Phase 2Completed
- Sponsor
- Genentech
- Start
- Feb 2005
- Primary completion
- May 2006
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of bevacizumab in ovarian epithelial cancer, primary peritoneal carcinoma (PPC), sponsored by Genentech. Started Feb 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian epithelial cancerprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00097019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00097019.